| Monoclonal antibodies |
TNF inhibitors
(Infliximab, Adalimumab, Certolizumab pegol), Afelimomab, Anrulizumab, Aselizumab, Atlizumab,
Atorolimumab, Azulizumab, Balizumab, Basiliximab, Belimumab,
Belizumab, Bertilimumab, Cedelizumab, Citilimumab, Clenoliximab, Daclizumab, Destilimumab, Doraglizumab, Dorlimomab aritox, Dorlixizumab, Dorlizumab, Drinalizumab, Durlizumab, Eculizumab, Efalizumab,
Elsilimomab, Erlizumab, Faralimomab, Fontolizumab, Galiximab, Gantenerumab, Gavilimomab, Golimumab, Gomiliximab,
Hylizumab, Ibalizumab, Inolimomab, Ipilimumab, Keliximab,
Lebrilizumab, Lerdelimumab, Lucalizumab, Lumiliximab, Maslimomab, Mepolizumab, Metelimumab, Morolimumab, Muromonab-CD3, Natalizumab, Nerelimomab, Ocrelizumab, Odulimomab, Omalizumab, Oteliximab,
Otelixizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab,
Talizumab, Teglizumab, Telimomab aritox, Teneliximab, Teplizumab, Tilolizumab, Tocilizumab, Toralizumab, Tralizumab, Treglizumab, Trelizumab,
Trilizumab, Ubrelizumab, Vapaliximab, Vepalimomab, Visilizumab, Xalizumab, Zanolimumab,
Ziralimumab, Zolimomab aritox, Zulizumab |
| -imus |
Abetimus,
Difirolimus, Dofosirolimus, Everolimus, Gifosirolimus, Gusperimus,
Pimecrolimus, Safosirolimus, Sirolimus, Tacrolimus, Temsirolimus,
Torolimus, Zotarolimus |
